Illumina, Inc.

Illumina, Inc.

Illumina, Inc.

Overview
Date Founded

2000

Headquarters

5200 ILLUMINA WAY, SAN DIEGO, CA, 92122, USA

Type of Company

Public

Employees (Worldwide)

7,800

Industries

Industrial Machinery & Manufacturing
Computer Software
Medical Support Services
Biotechnology

Company Description

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Illumina, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Vice President & Chief Administrative Officer

Senior Vice President & Chief Financial Officer

Chief Operations Officer

Senior Vice President & General Counsel

Senior Vice President, Chief Marketing Officer

Senior Vice President & Chief Technology Officer

Vice President & Chief Accounting Officer

Chief People Officer

Senior Vice President & Chief Medical Officer

Board of Directors

Former President & Chief Executive Officer at Illumina, Inc.

Director, President & Chief Executive Officer at Intuitive Surgical, Inc.

Linus Pauling Professor of Chemical Engineering, BioEngineering & Biochemistry & Director, Donna & Benjamin M. Rosen BioEngineering Center at California Institute of Technology

Venture Partner-Enterprise at Lightspeed Management Co. LLC

Special Partner at New Enterprise Associates

Former Chief Financial Officer, Director & Executive Vice President at PSEG Power LLC

Former Professional at Pacific Biosciences of California, Inc.

President & Chief Executive Officer at Illumina, Inc.

Apple Fellow at Apple, Inc.

Advisor at Medocity, Inc.

Paths to Illumina, Inc.
Potential Connections via
Relationship Science
You
Illumina, Inc.
Owners & Shareholders
Details Hidden

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm’s investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford’s analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Details Hidden

Edgewood Management primarily manages large-cap growth equity portfolios which pursue long-term appreciation driven by investment in a concentrated group of US growth stocks which Edgewood considers to be of a high quality. Portfolios primarily consist of the stock of approximately twenty-two (22) publicly traded companies. The firm identifies investments through research-driven fundamental analysis and employs a bottom-up approach in its investment analysis. Their Investment Committee incorporates both qualitative and quantitative inputs with bottom-up fundamental company analysis to identify the most appropriate securities to include in an investment portfolio. Edgewood Management is extremely valuation sensitive and typically has a three to five year holding period.

Details Hidden

In 1951, marking the 25th anniversary of the founding of Loomis, Sayles & Company, Robert H. Loomis sent a clear message to all clients. Click here to read. More than 60 years later, I echo the words of our founder when he said, "we wish to express our gratitude and appreciation to those who, through these difficult years, have helped us to the success we have enjoyed. We look to the future with humility but with confidence." The biggest difference in today's world is that our pace is faster and our playing field is larger. Given this scenario, our job at Loomis Sayles is to keep a laser-like “eye on the ball” particularly during times of uncertainty and volatility, where both risk and opportunity reside. My goal is to ensure that Loomis Sayles remains a broad-based, house of excellence trusted by our clients and recognized for our record of: Attracting and retaining exceptional investment professionals Providing caring, highly ethical and informative services to our clients Producing strong investment performance across our full stable of products The last five years have been a time of tremendous innovation for us. We have grabbed hold of opportunities presented by market upheaval to unearth some tremendous investments, build off our base and empower people to construct and test new capabilities. By integrating these with existing capabilities, (quantitative research, deeper risk analysis, greater macro-economic firepower, absolute return-oriented strategies and securitized capabilities), I believe we are a better investment firm than ever. On behalf of all Loomis Sayles employees, thank you for placing your confidence in us. From my personal vantage point, I am more confident than ever about the future of our company and the skills and passion of our people to deliver excellence in their work. We look forward to serving your investment needs as we face the ever-changing future together.

Recent Transactions
Details Hidden

Illumina, Inc. purchases Bluebee Holding BV

Details Hidden

Illumina, Inc. purchases Edico Genome Corp. from Qualcomm Ventures, Dell Technologies Capital

Details Hidden

Illumina, Inc. purchases GenoLogics Life Sciences Software, Inc. from OVP Venture Partners, GrowthWorks Capital Ltd., Yaletown Venture Partners, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onIllumina, Inc. issued USD Common Stock

Legal Advisor

Advised onIllumina, Inc. purchases NextBio Corp.

Underwriter

Advised onIllumina, Inc. issued USD Common Stock

Investment Advisor

Advised onIllumina, Inc. purchases Verinata Health, Inc.

Investment Advisor

Advised onIllumina, Inc. purchases Verinata Health, Inc.

Chair, Bankruptcy & Corporate Restructuring Practice

Advised onIllumina, Inc. purchases Verinata Health, Inc.

Advisors & Consultants
Legal Advisor

Founding Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at White & Case LLP

Clients

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

The School commits to dramatically advancing the art and science of medical care through an atmosphere of intense collaborative learning, social concern, and scholarly inquiry.

Our goal, at Myriad, is to make a difference in patient’s lives and for the past twenty years, the Company’s strategy has been guided by this mission. To accomplish this, we are focused on revolutionizing patient care through the development and marketing of transformative tests which address pressing clinical needs across multiple medical specialties. Over the last twenty years, Myriad has invested heavily in the education of patients and health care providers on the role genes and their related proteins play in disease. Almost one million patients have already benefited from Myriad’s informative testing, which helps physicians better manage their health care. Today, Myriad continues to build on this strong tradition. We are working to expand our reach by introducing new genetic tests and molecular diagnostic tests for a number of diseases. We also are focused on extending our mission internationally, in an effort to broaden our geographic footprint and provide critical information to more patients and healthcare providers

Key Stats and Financials As of 2021
Market Capitalization
$64.3B
Total Enterprise Value
$53.2B
Earnings Per Share
$4.43
Revenue
$3.24B
Net Profit
$656M
EBITDA
$767M
EBITDAMargin
23.68%
Total Debt
$1.91B
Total Equity
$4.69B
Enterprise Value / Sales
16.42x
Enterprise Value EBITDAOperating
68.41x
TEVNet Income
81.09x
Debt TEV
0.04x
Three Year Compounded Annual Growth Rate Of Revenue
5.58%
Non-Profit Donations & Grants
Investments
Details Hidden

Ginkgo Bioworks, Inc. engages in the development of microbe for different applications. Its organisms can be used for fuels, flavorings, fragrances, cosmetics, and pharmaceutical products. The company was founded by Thomas F. Knight Jr., Austin Che, Reshma Shetty, Bartholomew Canton and Jason Kelly in 2008 and is headquartered in Boston, MA.

Details Hidden

Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA.

Details Hidden

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

Investors
Details Hidden

Senvest employs a contrarian, value-based investment strategy. The firm uses a variety of methods of analysis including fundamental research, charting analysis, cyclical analysis as well as use of quantitative tools and investment approaches, or technical analytical tools and approaches. Their competitive strengths include a significant internal capital base that aligns interests with investors and enables them to pursue a long term, wealth creation strategy.

Details Hidden

CW's investment approach is to select relatively few high quality opportunities and then work actively and closely with the managing entrepreneurs to build businesses that dominate their sector. They focus exclusively on seed and early-stage healthcare investments.The firm seeks to develop a thorough understanding of a company or concept through multiple meetings with the principal entrepreneurs. During their due diligence process, they develop an in-depth understanding of relevant technologies, competitive companies, market dynamics and business economics. This input provides a basis for assessing technical, market, financial and management risks, and developing strategies to minimize these risks.The entire CW Group shares responsibility for performing the due diligence process and making the final investment decision. To ensure complete commitment, the firm makes investment decisions by consensus.

Details Hidden

Executive Chairman at Tenefit Corp.

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust. It engages in the ownership, operation, development, and redevelopment of life science and technology properties. The firm also provides a space for lease to the life science and technology industries, which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

AIMS APAC REIT Real Estate Investment Trusts | Singapore, Sgp

AIMS APAC REIT operates as a real estate investment trust, which invests in a diversified portfolio of income-producing and high quality industrial real estate located throughout Asia Pacific. It includes properties that support warehousing and logistics, business parks, light industries, high-tech, and manufacturing activities. The company was founded on December 5, 2006 and is headquartered in Singapore.

Sequenom Inc. Biotechnology | San Diego, CA

Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC.

Awards & Honors
Rank #912
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #36
2014
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Illumina, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Illumina, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Illumina, Inc..